C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages 1826-1832

  Takakuwa, Osamu ^a   Oguri, Tetsuya ^a   Ozasa, Hiroaki ^a   Uemura, Takehiro ^a   Kunii, Eiji ^a   Kasai, Daishi ^a   Miyazaki, Mikinori ^a   Maeno, Ken ^a   Sato, Shigeki ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Amrubicin; Amrubicinol; Lung cancer; NQO1; SNP

Indexed keywords

AMRUBICIN; AMRUBICINOL; BIOLOGICAL MARKER; DRUG METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (QUINONE); SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DNA POLYMORPHISM; GENE EXPRESSION; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

EID: 80054952395     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318229137d     Document Type: Article

References (31)

1. Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007;25:253-258. (Pubitemid 46774694)
2. Takeda K, Takifuji N, Negoro S, et al. Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007;25:377-383. (Pubitemid 46944847)
3. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26:5401-5406.
4. Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010;28:2598-2603.
5. Kaneda H, Okamoto I, Hayashi H, et al. Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401). J Thorac Oncol 2010;5:105-109.
6. Takakuwa O, Oguri T, Ozasa H, et al. Over-expression of MDR1 in amrubicinol-resistant lung cancer cells. Cancer Chemother Pharmacol In press.
7. Kuffel MJ, Reid JM, Ames MM. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 1992;30:51-57.
8. Yamaoka T, Hanada M, Ichii S, et al. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 1998;89:1067-1073. (Pubitemid 28544784)
9. Noguchi T, Ichii S, Morisada S, et al. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res 1998;89:1055-1060. (Pubitemid 28544782)
10. Schlager JJ, Powis G. Cytosolic NAD(P)H:(quinone-acceptor)oxi-doreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 1990;45:403-409. (Pubitemid 20087182)
11. Tani N, Yabuki M, Komuro S, et al. Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xeno-biotica 2005;35:1121-1133. (Pubitemid 43163250)
12. Misra V, Grondin A, Klamut HJ, et al. Assessment of the relationship between genotypic status of a DT-diaphorase point mutation and enzymatic activity. Br J Cancer 2000;83:998-1002.
13. Traver RD, Horikoshi T, Danenberg KD, et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 1992;52:797-802.
14. Ozasa H, Oguri T, Uemura T, et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 2010;101:161-166.
15. Fitzsimmons SA, Workman P, Grever M, et al. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996;88:259-269.
16. Okamoto I, Hamada A, Matsunaga Y, et al. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. Cancer Chemother Pahrmacol 2006; 57:282-288.
17. Morisada S, Yanagi Y, Noguchi T, et al. Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 1998;80:69-76.
18. Noguchi T, Ichii S, Morisada S, et al. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Jpn J Cancer Res 1998;89:1061-1066. (Pubitemid 28544783)
19. Ross D, Beall HD, Siegel D, et al. Enzymology of bioreductive drug activation. Br J Cancer Suppl 1996;27:S1-S8. (Pubitemid 26237917)
20. Malkinson AM, Siegel D, Forrest GL, et al. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cł. Cancer Res 1992;52:4752-4757.
21. Siegel D, Franklin WA, Ross D. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 1998;4:2065-2070. (Pubitemid 28415648)
22. Nioi P, Hayes JD. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat Res 2004;555:149-171. (Pubitemid 39359178)
23. Solis LM, Behrens C, Dong W, et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 2010;16:3743-3753.
24. Siegel D, Anwar A, Winski SL, et al. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol 2001;59:263-268. (Pubitemid 32108559)
25. Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999;94:803-807. (Pubitemid 29323895)
26. Smith MT, Wang Y, Skibola CF, et al. Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood 2002;100: 4590-4593. (Pubitemid 35429702)
27. Fagerholm R, Hofstetter B, Tommiska J, et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008;40:844-853. (Pubitemid 351913646)
28. Ross D, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 2004; 382:115-144. (Pubitemid 38240788)
29. Nakao M, Oguri T, Suzuki T, et al. Amrubicin monotherapy for elderly patients with previously treated lung cancer. Intern Med 2010;49:1857-1862.
30. Spanswick VJ, Cummings J, Smyth JF. Current issues in the enzymol-ogy of mitomycin C metabolic activation. Gen Pharmacol 1998;31: 539-544. (Pubitemid 28458921)
31. Ross D, Siegel D, Beall H, et al. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C. Cancer Metastasis Rev 1993;12:83-101. (Pubitemid 23220674)